Table 2.
Lymphocyte levels and subsets from patient number 1, 2, and 3 without JAK inhibitor treatment
| Lymphocyte subsets | P1 | P2 | P3 | Reference values |
|---|---|---|---|---|
| CD19+ | 0.15 | 0.35 | 0.02* | 0.09–0.4 × 10(9)/L |
| IgD-CD27+ | 8 | < 0.5* | 1* | 8–29% |
| CD3+ | 1.28 | 1.2 | 0.44* | 0.78–2.07 × 10(9)/L |
| CD4+ | 0.64 | 0.79 | 0.12* | 0.49–1.34 × 10(9)/L |
| CD8+ | 0.53 | 0.26 | 0.21 | 0.19–0.80 × 10(9)/L |
| CD4+CD25+CD127− | ND | 4* | 3* | 5–11% |
| CD4+CM | 25 | 74* | 50* | 14–48% |
| Th1/CD4+CM | 37* | 60* | 48* | 13–30% |
| Th2/CD4+CM | 19 | 16 | 40 | 14–53% |
| Th17/CD4 + CM | 13* | 3* | 1* | 20–37% |
| CD4+EM | 39 | 2* | 23 | 10–47% |
| Th1/CD4+EM | 40* | NA | NA | 44–79% |
| Th2/CD4+EM | 3* | NA | NA | 4–27% |
| Th17/CD4+EM | 4* | NA | NA | 8–28% |
| NK/CD16+/56+ | 0.11 | 0.31 | 0.10 | × 10(9)/L |
Lymphocyte levels and subsets were analyzed by flow-cytometry. P patient, JAK Janus tyrosine kinase, NA not assessable, ND not done. The following cell surface markers were used to identify B-lymphocytes: CD19, T lymphocytes; CD3, T helper cells; CD4, T cytotoxic cells; CD8, NK cells; CD16/56, switched memory B lymphocytes; IgD-CD27+, naïve T cells; IgD+CD27−, regulatory T lymphocytes; CD4+CD25+CD127−, CM central memory, EM effector memory. The bloodsample for P1 is from 2015, and for P2 and P3 from 2020. *Laboratory results out of normal range